Invitrogen Takes a Step Further Into Dx Reagent Market With Caltag Buy | GenomeWeb

Continuing its shopping spree for new protein-related technologies — and gaining another foothold in the diagnostic reagents market — Invitrogen this week said it will pay $20 million in cash to acquire Caltag Laboratories, a California manufacturer of immunological reagents.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: Platinum variant catalog, algorithmic strategy for upgrading fragmented assemblies, and more.

Sequencing of a 10,000-year-old mummy leads to its repatriation to the Fallon Paiute-Shoshone Tribe, Nature News reports.

The final text of the bill to reauthorize the America COMPETES Act might smooth over the differences between NSF and the House science committee, ScienceInsider says.

Four Republican lawmakers urge President-elect Donald Trump to keep Francis Collins as NIH director, Stat News reports.